ABSTRAa. Effects of s.c. administration of dexametha-status can be achieved (1-6), numerous side effects of steroid sone (1-25 wg/rat pupld) during the first 5 d postpartum therapy have been noted. These include sepsis (1, 3, 4), gastric on survival rates, body weight, heart weight, heart-to-body ulcers (I), hyperglycemia, necrotizing enterocolitis, pneumothoweight ratios, and heart dimensions were determined. osteomyelitis (3, 5) , and impaired weight gain and growth amethasone decreased survival, body weight, and heart (6). In addition, hypertension (1-3, 5, 7-9) and cardiac hypertroweight, but increased heart-to-body weight ratios and myo-phy (10, 11) have been identified as sequelae. However, neither cardial percentage of dry weight (0.44 to 0.52-1.06 and 20 the clinical course nor natural history of apparent cardiac hyperto 23%, respectively; p < 0.05) by 7 d postpartum. By 21 trophy have been documented in detail. Nevertheless, a recent d postpartum, differences in absolute body weight and heart study suggests that left ventricular hypertrophy is induced within weight between control and experimental animals were 3 wk of the onset of steroid therapy (two daily doses of 250 pg/ reduced; however, myocardial percentage of dry weight and kg, tapered at 3-d intervals over 5 wk) and that this hypertrophy heart-to-body weight ratios were indistinguishable. Micro-disappears over the ensuing 3 to 4 wk (12). scopic analysis of 7-d-old hearts disclosed that intervenEnhancing the benefits and reducing the adverse sequelae tricular septum, left ventricular free wall thicknesses, and attendant to steroid therapy of premature infants with BPD are left ventricle chamber diameter were reduced (0.93 to 0.76-immediate clinical objectives. Insights into how these objectives 0.85 mm, 1.19-1.34 to 0.92-1.07 mm, and 1.35-1.40 to might be realized can be acquired through a combination of 0.89-1.23 mm, respectively; p < 0.05), whereas right ven-clinical investigations characterizing physiologic parameters of tricular free wall thickness was unaffected and right ven-infants undergoing therapy and exploitation of animal models tricle chamber diameter was increased (0.29-0.31 to 0.42-in which salient side effects paralleling those encountered clini-0.46 mm) by dexamethasone. Thus, dexamethasone re-cally can be reproduced. This report describes a possible animal duced survival and retarded growth of neonatal rats. Re-model in which myocardial effects of steroid administration tardation of heart growth was less severe, producing a during the neonatal period can be explored at the cellular and transient relative cardiomegaly characterized by I) in-molecular levels. creased myocardial percentage of dry weight, 2) increased left ventricular free wall-to-chamber ratio, and 3) retention of absolute right ventricular free wall thickness. This rel- and heart-to-body weight ratios. These data suggest that were acquired pregnant from Charles River Breeding Laboratothis system might be a useful model for elucidating cellular ries (Wilmington, MA) or were mated at the Central Research and molecular mechanisms through which ventricular hy-Facility at Rhode Island Hospital. Rats were housed individually pertrophy might arise in infants receiving dexamethasone in plastic cages and provided food and water ad libitum. At term, therapy for bronchopulmonary dysplasia. (Pediatr Res 31: dams delivered their litters naturally and the number of pups in 359-363,1992) each litter was recorded. Subsequently, pups were allowed to nurse freely and remained with their mothers until 7 or 2 1 d PP.
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MATERIALS AND METHODS
ative cardiomegaly appeared to be resolved by 21 d postpartum, as reflected in myocardial percentage of dry weight Animal husbandry. Adult Sprague-Dawley rats (CD strain) and heart-to-body weight ratios. These data suggest that were acquired pregnant from Charles River Breeding Laboratothis system might be a useful model for elucidating cellular ries (Wilmington, MA) or were mated at the Central Research and molecular mechanisms through which ventricular hy-Facility at Rhode Island Hospital. Rats were housed individually pertrophy might arise in infants receiving dexamethasone in plastic cages and provided food and water ad libitum. Although growth retardation is not a consistent side effect of D E X therapy in infants (1 -12), our observations are consistent with earlier reports of growth retardation in animals after administration of co~ticosteroids (1 [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . This growth retardation has been attributed to suppression of D N A synthesis in some cases (20, 21) . The number of rat pups in a litter also can influence subsequent growth (22) . In particular, pups in large litters grow more slowly than pups from small litters. In this study, differences in litter size cannot account for the growth retardation observed (Table I) . First, control litters contained more pups, o n average, than DEX-treated litters. Second, the greatest growth retardation was observed in litters containing the fewest survivors. Thus, the growth retardation observed appears to be linked to DEX treatment and the associated mortality but not to the number of pups in the litter.
Heart growth of neonatal rats also was decreased by D E X (Tables 1 and 2 ). This was reflected in reduced 1) heart wet weight, 2) estimated heart volume, and 3) estimated heart mass. 
* Results are mean f I SEM Because heart volume and mass were estimated using methods that have not been validated for neonatal rat hearts, they cannot provide absolute measures of heart volume and mass. Nevertheless, their use as comparative indicators suggested that DEX reduced heart volume and mass relative to control rat hearts. Somewhat paradoxically, myocardial percentage of dry weight was increased by DEX (mean of up to 23.5% versus 19.8-20 .8% for control groups; Table 2 ). DEX did not suppress somatic growth and heart growth equally. In particular, heart growth seemed to be suppressed less than overall somatic growth. Moreover suppression of total somatic growth increased with increasing DEX dose, whereas suppression of heart growth was inversely correlated with DEX dose between 5 and 25 pg per injection (Table 1 ). This yielded dose-related increases in heart-to-body weight ratios ( Table 1) that were modest (1 3%) at low doses of DEX but substantial (2.3 times control) at higher doses.
Because the hearts of treated rats were decreased in absolute terms but enlarged relative to total body size, a relative cardiomegaly was produced. This relative cardiomegaly contrasts with observations of other investigators who have reported cardiac hypertrophy after administration of corticosteroids. However, important differences exist between this study and those of other investigators. For example, Clark et al. (23) and Kurowski et al. (24) conducted their studies on adult rabbits and mature rats (45 d old), respectively. In addition, the reports of Alpert (10) and Werner et al. (12) identify effects in humans within a few weeks of corticosteroid administration. Thus, significant cardiac growth would not be expected to occur in these cases. In contrast, Hicks et al. ( 1 9) document absolute hypertrophy in a rapidly growing system (chick embryos). However, in that study only a single dose of corticosteroid was administered. Moreover, the substance used was one that could be metabolized by the recipient (deoxycorticosterone acetate). Consequently, the manner in which the organism's glucocorticoid milieu is altered can profoundly influence the results obtained. For example, manipulation of glucocorticoid levels by administration of ACTH or of native glucocorticoids (which can be metabolized) would be expected to produce short-lived physiologic effects. In contrast, the consequences of manipulating glucocorticoid levels through administration of DEX (a synthetic glucocorticoid) might be expected to be long-lived. These differences are consistent with the pharmacologic and physiologic properties of diverse steroids in different models (25) .
The differential retardation of cardiac growth to total somatic growth suggests possible preferential sparing of heart muscle. This is consistent with the differential effects of DEX on several muscle types of adult rats observed by Kelly and Goldspink (26) . These investigators noted that DEX (2.5 mg/kg/d) led to atrophy of smooth and fast-twitch skeletal muscle, suppressed protein accumulation by slow-twitch skeletal muscle, and enhanced growth of cardiac muscle. Nevertheless, a positive effect of DEX on the hearts cannot be excluded. This possibility is raised by the increased percentage of dry weight of DEX-treated hearts (16-19% above controls; Table 2 ). To what this might be attributed cannot be determined from the data presented. However, other studies suggest that total glycosaminoglycan, glycogen, lipid ( 1 9), protein (26) , and intracellular nonglycogen fibrillogranular substances (chemically undefined, 23) might be increased. Further studies are in progress to explore these possibilities.
Despite a reduction in overall mass, the hearts from DEXtreated rats appeared somewhat hypertrophic or hyperplastic. Three considerations suggest this interpretation. First, cardiac dry weight was increased ( Table 2 ). This implies increased tissue mass and is consistent with hypertrophy (or hyperplasia). Second, RVFW was similar between control and DEX-treated animals ( Table 3 ). Maintenance of absolute RVFW thickness in association with reduced total heart size suggests relative hypertrophy (or hyperplasia) of right ventricular myocardium. Third, the relative mass of the left ventricular walls (LVFW and IVS) appeared to be increased (Table 3 ). This is suggested by expansion of the ratio of left ventricular walls relative to the LVc, which could reflect hypertrophy (or hyperplasia) of left ventricular myocardium. However, metabolic (e.g. RNA, protein, lipid, and glycogen content) and cellular (e.g. DNA content, cell numbers, and cell diameters) bases for these observations remain to be determined.
Similar increases in LVFW and IVS thicknesses relative to LVc were observed in human infants receiving DEX therapy for BPD by Werner et al. (12) . However, absolute LVFW and IVS thicknesses are increased in infants receiving DEX therapy, whereas the increases reported here are only relative. Although complete reconciliation of contrasting observations in these studies is not possible, differences in the extent of ontogenic maturation and growth rate between infants and neonatal rats must be considered as contributory factors.
To determine whether the relative cardiomegaly induced was permanent or transient, rats from several litters were allowed to develop for an additional 2 wk before being killed and evaluated. All surviving rats continued to grow, increasing total body weight and heart wet weight (compare Tables 1 and 4 ). However, rats that received DEX (12.5 pg per injection) apparently grew at a faster rate, inasmuch as their body weights were now 76% of control (37.3 k 5.0 versus 49.2 k 3.9 g; Table 4 ) as compared with being only 45% of control at 7 d PP (6.7 f 0.2 versus 14.9 f 0.2 g; Table 1 ). Similarly, the difference in heart wet weight between DEX-treated and control animals was reduced, although not to as great a degree (76% of control at 3 wk PP versus 64% of control at 7 d PP). Moreover, no differences in myocardial percentage of dry weight or in heart-to-body weight ratio could be found between control and DEX-treated rats. These observations suggest that the relative cardiomegaly induced by DEX treatment was transient. The transient nature of this apparent relative cardiomegaly parallels the transient hypertrophic cardiomyopathy in respirator-dependent human infants receiving high-dose DEX therapy for BPD reported by Werner et al. (12) .
Summary and conclusions. High-dose DEX therapy is frequently used in the management of respirator-dependent infants with BPD. This therapy produces numerous adverse side effects (1-6), including a recently documented transient hypertrophic cardiomyopathy (1 2). Although the clinical and pathophysiologic implications of these cardiovascular alterations are not yet characterized, a fuller appreciation of the role of DEX in the etiology of the ventricular hypertrophy encountered is warranted. The development of an animal model that reproduces or mimics the salient features of this ventricular hypertrophy can provide a powerful tool for achieving this objective.
Treatment of neonatal rats with DEX retarded total somatic growth and heart growth. Because somatic growth suppression correlated positively and heart growth suppression correlated negatively with increasing DEX dosage. heart-to-body weight ratios were increased by DEX treatment. Moreover, although absolute heart mass was reduced by DEX, myocardial percentage of dry weight was increased. Thus, DEX induced a transient relative cardiomegaly as determined by I ) increased heart-tobody weight ratio and 2) increased myocardial percentage of dry weight. In addition, this relative cardiomegaly was achieved at DEX concentrations similar to those used therapeutically that induce hypertrophic cardiomyopathy. Moreover, two major characteristics of this relative cardiomegaly parallel features of the hypertrophic cardiomyopathy seen clinically: 1 ) expansion of LVFW and IVS relative to LVc, and 2) resolution to apparent cardiac normalcy (reflected in heart-to-body weight ratio and myocardial percentage of dry weight in this study and in pretreatment dimensions of myocardial walls in the clinical study).
The results of this investigation suggest that the model described here can mimic certain, but not all, characteristics of a transient hypertrophic cardiomyopathy induced in respiratordependent infants receiving high-dose DEX therapy for BPD.
Consequently this model might be exploited to provide additional insights into the cellular and subcellular mechanisms through which DEX therapy for BPD induces this hypertrophic cardiomyopathy in infants.
